Extended Intensified Post-ASCT Consolidation with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (Dara-VRd) for Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL): The UK Optimum/Muknine Trial
| Autor: | Kaiser, Martin F., Hall, Andrew *, Smith, Isabelle *, de Tute, Ruth M. *, Roberts, Sadie *, Ingleson, Emma *, Bowles, Kristian M *, Garg, Mamta *, Lokare, Anand *, Messiou, Christina *, Houlston, Richard S. *, Jackson, Graham, Cook, Gordon *, Pratt, Guy *, Drayson, Mark T *, Owen, Roger G *, Brown, Sarah R *, Jenner, Matthew W * |
|---|---|
| Zdroj: | In Blood 15 November 2022 140 Supplement 1:1833-1835 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|